FY2026 Earnings Forecast for Nevro Issued By William Blair

Nevro Corp. (NYSE:NVRO) – Analysts at William Blair issued their FY2026 earnings per share estimates for shares of Nevro in a research note issued to investors on Tuesday, November 12th. William Blair analyst B. Vazquez expects that the medical equipment provider will post earnings per share of ($2.46) for the year. The consensus estimate for Nevro’s current full-year earnings is ($2.60) per share.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.40. Nevro had a negative return on equity of 23.35% and a negative net margin of 16.54%. The business had revenue of $96.60 million during the quarter, compared to analyst estimates of $93.09 million. During the same quarter last year, the company posted ($0.65) EPS. Nevro’s revenue for the quarter was down 7.0% on a year-over-year basis.

Other equities research analysts have also issued reports about the company. Truist Financial reduced their price target on Nevro from $10.00 to $5.50 and set a “hold” rating for the company in a report on Thursday, August 8th. Royal Bank of Canada reissued a “sector perform” rating and issued a $7.00 price objective on shares of Nevro in a research note on Tuesday. Citigroup cut their price objective on Nevro from $6.89 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 1st. Canaccord Genuity Group cut their price objective on Nevro from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, Robert W. Baird raised their price objective on Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating and twelve have assigned a hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.10.

Nevro Trading Down 8.7 %

Shares of NYSE NVRO opened at $4.07 on Wednesday. Nevro has a one year low of $4.00 and a one year high of $22.64. The firm has a market capitalization of $151.56 million, a PE ratio of -2.14 and a beta of 0.93. The company has a current ratio of 4.77, a quick ratio of 3.53 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $5.21 and a two-hundred day moving average price of $7.42.

Institutional Trading of Nevro

Several institutional investors have recently modified their holdings of NVRO. Assenagon Asset Management S.A. grew its holdings in shares of Nevro by 490.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 728,463 shares of the medical equipment provider’s stock worth $6,134,000 after purchasing an additional 605,134 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Nevro by 130.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider’s stock worth $5,590,000 after purchasing an additional 566,462 shares in the last quarter. Engaged Capital LLC grew its holdings in shares of Nevro by 29.5% during the 3rd quarter. Engaged Capital LLC now owns 2,442,956 shares of the medical equipment provider’s stock worth $13,656,000 after purchasing an additional 557,000 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Nevro by 21.4% during the 2nd quarter. Millennium Management LLC now owns 956,542 shares of the medical equipment provider’s stock worth $8,054,000 after purchasing an additional 168,573 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Nevro by 3,446.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 152,500 shares of the medical equipment provider’s stock worth $1,284,000 after purchasing an additional 148,200 shares in the last quarter. Institutional investors and hedge funds own 95.52% of the company’s stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.